Garde Capital’s Gilead Sciences GILD Stock Holding History

Garde Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-80	Closed	-$8.87K	–	468
2025 Q2	$8.87K	Hold	80	–	–	﹤0.01%	515
2025 Q1	$8.96K	Buy	+80	New	+$8.26K	﹤0.01%	494
2023 Q3	–	Sell	-3,680	Closed	-$284K	–	265
2023 Q2	$284K	Buy	+3,680	New	+$293K	0.02%	193
2019 Q1	–	Sell	-8,070	Closed	-$505K	–	151
2018 Q4	$505K	Hold	8,070	–	–	0.09%	108
2018 Q3	$563K	Hold	8,070	–	–	0.09%	105
2018 Q2	$572K	Sell	8,070 -100	-1%	-$7.06K	0.1%	102
2018 Q1	$616K	Sell	8,170 -160	-2%	-$12.7K	0.11%	94
2017 Q4	$597K	Hold	8,330	–	–	0.11%	96
2017 Q3	$675K	Buy	+8,330	New	+$637K	0.13%	90
2016 Q4	–	Sell	-7,500	Closed	-$736K	–	138
2016 Q3	$736K	Buy	+7,500	New	+$609K	0.24%	74
2015 Q4	–	Sell	-7,500	Closed	-$736K	–	124
2015 Q3	$736K	Buy	7,500 +5,500	+275%	+$611K	0.24%	74
2015 Q2	$234K	Buy	+2,000	New	+$219K	0.07%	131
2014 Q4	–	Sell	-1,945	Closed	-$207K	–	140
2014 Q3	$207K	Buy	+1,945	New	+$190K	0.08%	99

Other funds holding GILD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Garde Capital's GILD Position: Q3 2025 in Review

Garde Capital sold out of Gilead Sciences (GILD) in Q3 2025, closing a stake of 80 shares — an estimated $8.87K sold.

Garde Capital first reported a position in GILD in Q3 2014 and held it in 13 quarters. The position peaked at $736K in Q3 2016. 2,032 funds tracked by Wall St. Rank hold GILD as of Q3 2025.

Garde Capital reported no remaining Gilead Sciences position as of Q3 2025 after selling out during the quarter.
Garde Capital sold 80 Gilead Sciences shares in Q3 2025, an estimated $8.87K.
Garde Capital first reported a position in Gilead Sciences in Q3 2014 and held it in 13 quarters.
Garde Capital's Gilead Sciences position peaked at $736K in Q3 2016.
2,032 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2025.

Based on Garde Capital's 13F filing for Q3 2025, filed 16 Dec 2025.